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I
schemic heart disease (IHD) was the leading cause of death worldwide in 2010. 1 However, many acute myocardial infarction (AMI) patients survive, and many adults live with disabling symptoms of stable angina pectoris or ischemic heart failure. Measuring the global burden of IHD requires estimating IHD mortality, prevalence, and disability for men and women, by age and world region. Nonfatal IHD incidence and prevalence do not always correlate with IHD mortality. For example, improved acute and chronic IHD treatments may lead to both decreased IHD mortality and a growing population of chronic IHD survivors. Conversely, even if IHD incidence is high, high case fatality may lead to relatively low prevalence. Regardless of the time trend in age-standardized in high-income region AMI epidemiology studies of until ≈1995 to 2000, and are rarely measured in many low-and middle-income regions to this day. The GBD 2010 Study therefore recorded the use of troponin enzyme measurement in AMI studies and planned a priori to adjust incidence estimates for troponin measurement.
Estimating Nonfatal IHD Incidence and Prevalence
YLL (early deaths) and YLD (nonfatal disability) that make up DALYs were calculated in relation to hypothetical age-specific reference life expectancies (for example, 86.0 years at birth) derived from life-table methods. 1, 11 IHD mortality and YLL estimation methods and results are reported separately. 12,12a IHD YLDs were calculated from AMI incidence and angina and ischemic heart failure prevalence estimated for the year of interest. We used DisMod-MR (Disease Model-Meta Regression, Institute for Health Metrics and Evaluation, Seattle, WA) to estimate the incidence and prevalence of nonfatal IHD outcomes with the use of systematic review study data, adjusting for covariates (Online-only Data Supplement Methods). 4 DisMod-MR estimates a generalized negative binomial model for all the epidemiological data with fixed and random effects. 13 A negative binomial model regression model was the appropriate model for counts data (prevalent cases). A mixed-effects design was chosen to include not only universal fixed effects associated with IHD, but also random effects capturing heterogeneity at each level of the study's nested geographic design (eg, country within region within super region). Fixed effects included age effects, effects for covariates that predict country variation in the quantity of interest, and effects that predict variation across studies owing to the attributes of the study. Study-level fixed-effects covariates included case definition, diagnostic method, or source of data, and country-level fixed-effects covariates included income per capita, health system performance, and age-standardized IHD mortality rate. Random effects were implemented as super region, region, and country random intercepts. The data were modeled with Bayesian methodology using vague previous distributions. The uncertainty of estimates are described with Bayesian credible intervals as opposed to confidence intervals (Methods in the online-only Data Supplement). Both approaches yield similar numeric results in large samples. 14 Covariates entered into the AMI DisMod-MR model were GBD region, country, sex, age-standardized AMI death rate, and, if studies reported on only nonfatal or all MI, only first-ever or both firstever and repeat AMI, and the measurement of troponin biomarker. Age-standardized AMI death rates were estimated by using the IHD Figure 1 . Ischemic heart disease (IHD) disease model, the Global Burden of Disease 2010 Study. AMI indicates acute myocardial infarction; CHF, congestive heart failure; and MI, myocardial infarction.
by guest on November 6, 2017 http://circ.ahajournals.org/ Downloaded from mortality and MI/IHD death rate ratio, the latter conditioned on age, sex, national income, country, and region. IHD risk factors (eg, smoking, mean cholesterol and blood pressure, nutritional factors, income, and health system access) contributed to the AMI mortality covariate and were not directly entered into the AMI model.
Mostly because of the broad geographical coverage of the World Health Survey (WHS), angina prevalence data were obtained for 90 countries and 18 GBD regions. Covariates entered into the DisMod-MR angina model were GBD region, country, sex, agestandardized IHD death rate, and measurement method (self-report versus physician-reported; Rose probable versus Rose definite angina), and source survey. WHS angina prevalence was 21% higher overall than all other surveys.
IHD is only one of several causes of heart failure, so the first step for heart failure estimation was to estimate a total heart failure prevalence envelope. Total heart failure prevalence was estimated by DisMod-MR with the use of systematic review, US Medical Expenditure Panel Survey self-report, and multinational (24 countries) hospital discharge data in a model including covariates for GBD region, nation, sex, age-standardized cardiomyopathy death rate, New York Heart Association classification, body mass index, and self-reported versus physician's diagnosis. 4, 12 A meta-analysis of clinic-based studies reporting heart failure causes and hospital discharge data from the United States, Canada, Brazil, and Mexico guided region-specific allocation of the heart failure envelope to IHD and 6 other principal causes.
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DALY Weight Estimation and Severity Distributions
GBD disability weights range from no disability (weight=0.00) to death (weight=1.00). Weights for each IHD health state were estimated by using health state valuation of lay health state descriptions in population-based health surveys and an open Web-based survey. 15 Lay descriptions for 3 distinct angina and heart failure states of graded severity (mild, moderate, and severe) were based on Canadian Cardiovascular Society class descriptions 16 and New York Heart Association symptom classification descriptions, respectively (Table  I in the online-only Data Supplement). 17 Two study investigators (A.E.M. and G.A.M.) wrote lay descriptions for 2 AMI states (days 1-2 and days 3-28). Distribution of severity for each sequela was based on the distribution of symptom severity in studies of angina patients 16 and the distribution of Short Form 12 quality-of-life ratings among US Medical Expenditure Panel Survey patients with heart failure.
The first AMI period started immediately after an AMI attack and lasted, at most, 2 days (10% of duration, disability weight 0.422, 95% uncertainty interval [0.284-0.566]; Table I in the online-only Data Supplement). The second period lasted from 3 to a maximum of 28 days (disability weight 0.056 [0.035-0.082]; 90% of duration). Angina and heart failure disability weights were applied to prevalent cases for the entire year of interest. With the use of Canadian Cardiovascular Society classes, 16 angina disability was distributed as mild (27% of angina patients), moderate (19%), and severe (54%). Restricting to New York Heart Association ≥class 2 heart failure, the ischemic heart failure disability was distributed as mild (23% of ischemic heart failure), moderate (22%), and severe (55). Averaging over the severity distributions, the summary disability weight for angina was 0.113, and the summary disability weight for ischemic heart failure was 0.126. Pharmaceutical therapy or revascularization procedures may relieve angina symptoms. Based on the proportion of patients with stable angina who were symptom free (ie, successfully treated) at baseline in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation trial, we estimated that, in the United States, about one-fifth of patients with stable angina are successfully treated and symptom free. 18 In a sensitivity analysis, we reestimated stable angina YLD, assuming one-fifth of patients in high-income regions are treated and symptom free (0.8×DALY weight).
Angina and heart failure may coexist or occur along with other comorbid illnesses. Because of the lack of data on comorbid illness disability weighting, country-specific microsimulations were used to estimate the probability of comorbidity (eg, angina and heart failure together), assuming independence (Online-only Data Supplement Methods). Disability from multiple comorbid conditions was assumed to be a multiplicative effect of disability from the individual diseases and was calculated as one minus the product of one minus each disability weight. The method was validated by repeating the procedure with US Medical Expenditure Panel Survey participants by using International Classification of Diseases-coded conditions, and resulting distribution of DALY weights matched well with the distribution of self-reported quality of life on the Short Form 12 scale in persons with multiple comorbid conditions (correlation coefficient=0.999).
AMI incidence, angina and heart failure prevalence, YLDs and DALYs for 21 GBD regions from 1990 to 2010 are reported either as absolute numbers or by dividing these quantities by the regional populations. Age standardization and dividing by population at risk allowed the analysis of changes in IHD rates and prevalence independent of changes in population size and age structure. Age standardization was done by the direct method, by using 5-year GBD age categories and the World Health Organization standard population. The independent influences of population aging and population growth on change in total DALYs between 1990 and 2010 were assessed by (1) computing the numbers of DALYs expected assuming a scenario of the same population growth to 2010 but with a 1990 age structure, and (2) computing the number of DALYs expected in scenario with the real 2010 age structure assuming no population growth since 1990.
Results
Nonfatal IHD in 21 World Regions in 1990 and 2010
In 2010, the Eastern Europe and Central Asia regions-the regions of the former Soviet Union-had the highest agestandardized AMI incidence rates in the world (>340 per 100 000 in males and >180 in females; Table II in the onlineonly Data Supplement). Lowest AMI incidence was estimated for the High Income Asia/Pacific and East Asia regions (both <140 AMI per 100 000 in males and <80 in females).
Globally, age-standardized AMI incidence in all ages decreased from 1990 to 2010, from 222.7 to 195.3 per 100 000 in males and from 136.3 to 115.0 in females. Age-standardized AMI incidence declined the most in Australasia, Western and Central Europe, and North America High Income (all decreases of >87 per 100 000 in males and >35 in females). AMI incidence increased the most in Eastern Europe (62 per 100 000 increase in males and 17 in females). In the majority of other regions, AMI incidence decreased modestly.
Age-standardized angina prevalence decreased globally, from 21.9 to 20.3 per 100 000 in males and from 17.7 to 15.9 in females. Prevalence decreased ≥5.0 percentage points in males and ≥3.9 percentage points in females in Australasia, Western Europe, and North America (Table III in the online-only Data Supplement). Other regions had modest decreases in angina, with the exceptions of small increases in South Asia, Central Asia, Western sub-Saharan Africa (males and females), and Eastern Europe (males only).
Global ischemic heart failure prevalence increased from 2.4 to 2.7 per 100 000 in males and remained at 1.9 in females between 1990 and 2010. Small increases in age-standardized ischemic heart failure prevalence were almost uniform across the 21 GBD regions (Table IV in the online-only Data Supplement). regions (Table V in the online-only Data Supplement). For several low-and middle-income regions (South Asia, North Africa/Middle East, and the sub-Saharan Africa), the average age at first AMI was <65 years, and the average age at first angina was <55 years. The highest rates of IHD disability in 2010 were found in Eastern Europe and Central Asia (Figure 2 ). Prevalent stable angina contributed the most to IHD disability, followed by smaller contributions from ischemic heart failure and nonfatal AMI (Figure 3 ). Absolute numbers of IHD YLDs increased in all regions from 1990 to 2010, ranging from a 15% to 33% increase in high-income regions and from a 13% to 100% increase in low-and middle-income regions (Table VI in the online-only Data Supplement). Owing to fewer data and uncertainty around estimates in the source epidemiological data, the uncertainty intervals around IHD YLD estimates (based on nonfatal IHD) were much wider than those for YLL (based on IHD mortality; Methods and Figure II in the onlineonly Data Supplement).
Disability Adjusted Life-Years Attributable to IHD in 1990 and 2010
Four regions-Western Europe, Central Europe, Australasia, and North America-experienced a decrease in absolute IHD DALYs and age-standardized IHD DALYs per 100 000 population between 1990 and 2010, despite demographic changes in the interval (Table; Table VII in the online-only Data Supplement). With the exception of Eastern Europe and Central Asia, the regions with the highest IHD mortality rates, the rest of the world had larger relative 20-year increases in YLD than in DALYs. Eastern Europe, Central Asia, North Africa/Middle East, and South Asia had the highest age-standardized DALYs per 100 000 in the world in 2010 (Figure 4) . DALY rates trended upward in these and other low-and middle-income regions after 1990, but appeared to flatten in most, but not all regions after 2005 (Table) .
The absolute global burden of IHD increased by 29 million DALYs (29%) between 1990 and 2010 (Table VIII in the online-only Data Supplement). IHD DALYs increased 32.4% globally between 1990 and 2010 because of the aging of the world population and increased 22.1% because of increased population. These increases were attenuated by a 25.3% decrease in combined age-standardized, per capita IHD DALY rate. In general, population growth contributed most to IHD DALY increases in low-and middle-income regions, and aging contributed the most in high-income regions. However, within low-and middle-income regions, population growth was the main driver of DALY increases in South Asia, North Africa/Middle East, and sub-Saharan Africa, but aging drove DALY increases more in the former Soviet Union regions and in Latin America and the Caribbean.
Despite higher age-standardized rates of fatal and nonfatal IHD in males, the proportion of male global burden of disease attributable to IHD (7%) was only slightly higher than the female IHD proportion (5%; Figure 5 ). Overall, nonfatal IHD (YLDs) contributed much less than IHD mortality (YLL) to global IHD DALYs (YLL attributable to premature IHD deaths constituted 94% of IHD DALYs in men and 92% of IHD DALYs in women).
Sensitivity Analyses
When acute unstable angina disability was added to AMI disability, total IHD YLD increased by 0.4% in males and 0.3% in females, and acute coronary syndromes went from accounting for 0.5% to 0.9% of YLD in males and from 0.4% to 0.7% of YLD in females; overall IHD DALYs were increased by 0.02%. When we assumed that one-fifth of angina patients in high-income regions were successfully treated and asymptomatic, overall IHD YLD decreased by 3.7% in males and females, and IHD DALYs decreased by 0.2% in males and 0.3% in females. 
Discussion
The global burden of IHD in 2010 presents a mixed picture: progress is evident in the reduced age-standardized IHD burden since 1990, especially in high-income regions; however, at the same time, high IHD burden was found in a geographic band including the former Soviet Union territories, North Africa, the Middle East, and South Asia. Aging populations and population growth in many regions have increased both YLD and IHD burden worldwide. This finding is consistent with the ascendance of chronic, noncommunicable diseases found in the GBD 2010 Study as a whole. 1 Since 1990, the number of years of disability attributable to nonfatal IHD has grown faster than IHD mortality, although the absolute numbers of nonfatal disability years were dwarfed by YLL attributable to IHD deaths.
Although nonfatal IHD contributed little to DALYs, the relatively steeper increase in YLD in comparison with mortality and YLL suggests the need for a strategy shift in IHD treatment. IHD death rate and case fatality will no longer be the sole public health benchmarks; improved quality of life in patients with chronic IHD will be an important secondary outcome. Interventions designed to relieve symptoms and improve fitness and vitality in patients with chronic angina and heart failure are needed. The mainstays of chronic IHD treatment are standard, low-cost medications that are sadly insufficiently used in patients who have chronic cardiovascular disease worldwide, especially in low-and middle-income regions. The Prospective Urban Rural Epidemiological (PURE) study found that among patients with cardiovascular disease, 11% of high-income region patients were not taking any standard secondary prevention drugs and 80% of lowerincome region patients were taking none of the medications. 19 Overall in PURE, countries' health expenditure per capita correlated positively with the percentage of use of standard secondary prevention medications, although, in several cases, better medication coverage was achieved by countries at the same or lower health expenditures.
Although AMI incidence remains high in many regions, nonfatal AMI burden was lower than angina and ischemic heart failure burden owing to the assumption that, absent associated angina or heart failure, AMI symptoms do not persist beyond 30 days. Assuming an added nonfatal IHD burden owing to acute unstable angina (and symptom severity the same as AMI), YLD increased only 0.3% to 0.4%, and acute unstable angina plus AMI (acute coronary syndromes) increased overall IHD burden by 0.02%. Prevalent cases of stable angina contributed the most to the burden of nonfatal IHD. All angina diagnoses in the source studies relied on a subjective, self-reported measure. Studies using a gold standard of objectively measured exercise-induced ischemia accompanying chest pain found that the Rose questionnaire had 40% to 67% sensitivity and 56% to 80% specificity and a much lower positive predictive value in women than in men. 19a,20 However, Rose questionnaire definite angina has been associated with higher IHD mortality, 21 and there is a growing body of evidence that many cases of angina, especially in women, are associated with microvascular coronary atherosclerosis not identifiable with coronary angiography. [22] [23] [24] More enigmatic was the pattern of generally higher angina prevalence relative to regional IHD mortality elicited by using the Rose questionnaire in the WHS, especially in the sub-Saharan African WHS sites. It is unknown whether this pattern represents a systematic bias (due, for example, to using a measurement tool not properly validated in diverse populations), or an emerging higher prevalence of IHD in sub-Saharan Africa preceding changes in IHD mortality. Unlike the largest meta-analysis of Rose questionnaire angina published to date, we did not find angina was more prevalent in women than in men. 25 IHD measurement problems would best be addressed by improved methods of health surveillance, including an investment in better interview or objective diagnostic screening methods applicable to lowincome settings.
The global pattern of ischemic heart failure prevalence estimated by the GBD 2010 Study was similar to the few past studies of regional differences in heart failure causes. 26 To adjust for the effect of the advent of troponin biomarker on AMI incidence around the turn of the 21st century, we adjusted for troponin measurement. This adjustment standardized comparisons of AMI incidence between 1990 and 2010, but may have biased AMI incidence estimation for regions that continue without access to troponin and other AMI diagnostic tools. The case mix of ST-and non-ST-elevation AMI and the potential impact of implementing improved diagnostic tools in many regions remain unknown.
For nonfatal IHD incidence, prevalence, and case fatality, we depended predominantly on data gathered from a large systematic literature review. Inevitably, these studies usually sampled only a subset of the populations studied, and portions of the population went unrepresented. This was particularly true of the usually small studies from lower-income regions. For example, despite an extensive literature review of data published over a 28-year period, no studies of AMI incidence or case fatality were included for sub-Saharan Africa regions, and almost all sub-Saharan Africa estimates of angina prevalence come from 1 study (the WHS, 2002-2004). 4 DisMod-MR used a Bayesian method that allowed us to start with a priori general epidemiological characteristics of IHD obtained from the aggregate study-level data compiled from the systematic review (pattern of prevalence over the lifespan, consistent relationships between incidence, prevalence, and mortality), and allow geographic, temporal, and age-related heterogeneity to revise these previous assumptions because it is applied to specific countries, ages, and years. A mixed, multilevel model reflected the geographical nesting of the study design. However, DisMod-MR has limitations. Bayesian methods run the risk of relying on expert opinion to set the previous assumptions, and these assumptions may be false, particularly for countries with sparse data.
For the estimation of prevalence for each IHD sequela, adjustment was made for known sources of bias. For AMI, adjustment was made for the outcome definition (incidence rate versus event rate) and measurement method (use of troponin biomarker or not). For angina, adjustment was made for the measurement method (Rose questionnaire or other method) and for the WHS versus other surveys. For heart failure, adjustment was made for the case definition and range of symptom severity used in the study. Sources of uncertainty surrounding nonfatal IHD source data were propagated forward to GBD summary estimates, resulting in much larger credible intervals around IHD YLD (nonfatal) estimates than for IHD YLL (mortality) estimates (Figure II in the onlineonly Data Supplement). Although the geographic coverage for angina prevalence was broader than for the other IHD sequelae-largely because of the WHS-angina estimation was the most prone to bias. This vulnerability stemmed from 
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the subjective nature of self-report, and perhaps the cultural context in which the questions were interpreted by survey participants. AMI cases are likely systematically underdiagnosed in lower-resource regions because of less access to health facilities and scarcity of diagnostic technology. Parts of countries and regions with higher IHD rates may have been more likely to be studied and contribute data. Despite our efforts to adjust estimates to account for bias, we could not completely compensate for regions with sparse data, nor could we adjust for unmeasured sources of bias Our results showed that, with the use of the DALY metric, global IHD burden was dominated by fatal IHD (YLL), nonfatal IHD made only a minor contribution, and acute nonfatal IHD (AMI or unstable angina) made the least contribution. It is important to note that, as a metric of societal disease burden, DALYs are a measure of health loss only, not financial or productivity loss because of disease (eg, financial costs of hospitalization or chronic medications, lost work time, and family or other caregiver burden related to nonfatal IHD).
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Implications
Despite decreasing age-standardized IHD incidence and mortality rates in most regions, population growth and aging has increased the global burden of IHD since 1990. Nonfatal IHD (nonfatal AMI, angina, and ischemic heart failure) has increased more than IHD deaths since 1990, but IHD mortality remains the greatest contributor to disease burden. Underlying global IHD burden trends are substantial regional differences in rates and time trends of AMI, angina, ischemic heart failure, and IHD mortality.
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Objectives of the Global Burden of Disease 2010 Study 1, 2
The Global Burden of Diseases, Injuries, and Risk Factors (GBD) enterprise is a systematic, scientific effort to quantify the comparative magnitude of health loss due to diseases, injuries, and risk factors by age, sex, and geography for specific points in time. The GBD construct of the burden of disease is health loss, not income or productivity loss. For decision makers, health-sector leaders, researchers, and informed citizens, the GBD approach provides an opportunity to see the big picture, to compare diseases, injuries, and risk factors, and to understand in a given place, time, and age-sex group what are the most important contributors to health loss.
Measuring disease and injury burden in populations requires a composite metric that captures both premature mortality and the prevalence and severity of ill-health. The 1990 Global Burden of Disease study proposed disability-adjusted life years (DALYs) to measure disease burden. No comprehensive update of disease burden worldwide incorporating a systematic reassessment of disease and injuryspecific epidemiology has been done since the 1990 study. We aimed to calculate disease burden worldwide and for 21 regions for 1990 and 2010 with methods to enable meaningful comparisons over time.
Glossary: Disability-adjusted life years and Global Burden of Disease definitions 1, 2
 Disability-adjusted life years (DALYs) are a summary metric of population health. DALYs represent a health gap; they measure the state of a population's health compared to a normative goal. The goal is for individuals to live the standard life expectancy in full health.  DALYs are the sum of two components: years of life lost due to premature mortality (YLLs) and years lived with disability (YLDs).  YLLs are computed by multiplying the number of deaths at each age x by a standard life expectancy at age x. The standard selected represents the normative goal for survival and has been computed based on the lowest recorded death rates across countries in 2010.  YLDs are computed as the prevalence of different disease-sequelae and injury-sequelae multiplied by the disability weight for that sequela. Disability weights are selected on the basis of surveys of the general population about the loss of health associated with the health state related to the disease sequela.  DALYs are an absolute measure of health loss; they count how many years of healthy life are lost due to death and non-fatal illness or impairment. They reflect the number of individuals who are ill or die in each age-sex group and location. Population size and composition influences the number of DALYs in a population.  The GBD 2010 disease-and-injury-cause list is a hierarchical list of 291 diseases and injuries. At the first level of disaggregation causes are divided into three broad groups: communicable, maternal, neonatal, and nutritional disorders; non-communicable diseases; and injuries. At each level in the hierarchy, the cause list provides a set of mutually exclusive and collectively exhaustive categories.  Sequelae-in total, we have identified 1160 sequelae of the 291 diseases and injuries. For example, diabetic neuropathy is a sequela of diabetes mellitus. To avoid double counting, a sequela can only appear in the cause-sequela list once even if the same outcome might be claimed by more than one disease.  Health states-across the 1160 sequelae, 220 unique health states were identified. For example, both malaria and hookworm have mild anaemia as a sequela. Mild anaemia is a unique health state. The list of unique health states serves two purposes: (a) to allow assessment of the total burden of some health states such as anaemia across various causes; and (b) to simplify the task of measuring disability weights for sequelae.  DALYs presented in this study are not age-weighted and are not discounted for time preference. Base case tabulations for the GBD 1990 and GBD 2000 studies used age-weighting and a 3% discount rate.
Description of Disease Model, Meta-Regression (DisMod-MR)
Bayesian Meta-Regression for Epidemiological Estimation in the GBD Study 2010
A. Introduction
While the density of data and types vary tremendously across diseases and their sequelae, there are a number of common challenges in the estimation of the prevalence of non-fatal outcomes. First, to a varying degree there is data sparsity in many regions for most outcomes. Sparse data mean that predictions of prevalence need to take advantage of relationships to covariates in the metaregression or default to the average of a region, super-region, or the world. Second, in regions or countries with multiple measurements, the results are often highly heterogeneous. The degree of heterogeneity is far beyond what is expected on the basis of sampling error and indicates considerable non-sampling variance. The sources of non-sampling variance include sample design, implementation issues in data collection, case definitions, and diagnostic technologies. Third, published studies often use non-standard age-groups like 18-35 or 15 and above. For the GBD Study 2010, we need to use data from many different non-standard age-groups to generate coherent estimates for the 20 age-groups for the study. Given that prevalence for most sequelae are strongly related to age, this issue is particularly important. Fourth, data for conditions are collected for many different outcomes such as incidence, prevalence, remission, excess mortality, or cause-specific mortality. The mix of data varies across diseases and across regions for a disease. All of these sources provide some relevant information for estimating prevalence but more often than not are not strictly comparable due to variations in case definition or other methodological differences. Fifth, within regions or countries, the true prevalence for a sequela can vary enormously. The high level of hepatitis C in Egypt is an example in the North Africa and Middle East region. Such within-region heterogeneity in the true rates must be accommodated in a meta-regression framework. Sixth, based on biology we may have strong priors on the age pattern of incidence or prevalence for a condition; for example, we expect the incidence of many cancers to increase with age due to cumulative exposure to carcinogens at least until some adult age. Another example is no bipolar disorder at very 3 young ages. Seventh, for many conditions, the available studies use different case definitions. The review of diabetes prevalence studies identified 18 different case definitions in use. For angina pectoris, cases were defined using the Rose questionnaire or self-reported diagnosis. For AMI, incidence was expected to vary based on use or non-use of troponin biomarker measurement. If all non-reference definition data are excluded, predictions can be based on an extremely limited number of studies only. An alternative is to empirically adjust ("cross-walk") between different definitions using the overlap in available studies.
To address these common estimation challenges, we have developed a Bayesian meta-regression tool specifically for the GBD 2010, DisMod-MR. This tool estimates a generalised negative binomial model for all the epidemiological data with various types of fixed and random effects. These include age fixed effects, fixed effects for covariates that predict country variation in the quantity of interest, fixed effects that predict variation across studies due to attributes of the study protocol, and superregion, region, and country random intercepts. We divide this section of the appendix into several sections to explain the different uses of DisMod-MR: 1) the basic DisMod-MR estimation equation for prevalence; 2) how DisMod-MR uses data from different age intervals; 3) use of expert priors; 4) use of data on multiple epidemiological parameters simultaneously; 5) posterior estimation by region; and 6) predictions from 1990, 2005, and 2010.
B. Prevalence Estimation Equation
DisMod-MR can be used to estimate age-sex-country specific prevalence from heterogeneous and often sparse data sets. The estimation equation for the generalised negative binomial with random and fixed effects has the form:
Where p i is the prevalence of observation i; π i is the expected value of this prevalence, δ i is the dispersion, and n i is the effective sample size of the observation. Γ denotes the gamma function, π(a) is the age-specific piecewise linear spline (defined below), α is a vector of random effects, β and β' are vectors of fixed effects, U i is a row of the random effect design matrix, X i and X i ' are rows from the fixed effect country-prediction and cross-walk design matrices, and w i (a) is the age-specific population weight structure. σ l is the standard deviation for random effects at level l of the spatial hierarchy, and l(j) is the level of random effect j. η is the log of the negative binomial dispersion parameter at the reference level, ζ is the generalised negative binomial fixed effect vector and Ζ i is a row from the corresponding design matrix.
The age-specific piecewise linear spline π(a) has a set of model-specific knots {a 1 , …, a K } and is defined by the equation: 4 where and γ k are the age fixed effect parameters. There are two types of fixed effects from covariates included in this model. X i are covariates that explain variation across populations in the prevalence rate for the condition being analyzed (Country Level fixed effects covariates). These covariates are selected by the analyst as in any traditional regression. In addition, covariates X i ' can be included, which are variables that characterize determinants of the observed rate in a study that are not related to the underlying rate in the community but characteristics of the study design, instrument or implementation (Study Level fixed effects covariates). For example, X i ' variables may be dummy variables for alternative case definitions used in different studies. When using X i ' variables in DisMod-MR, predictions for true prevalence are based on setting these variables to a reference value.
For IHD sequelae, the following fixed effects were modeled: DisMod-MR includes nested random intercepts for π in the generalised negative binomial in a hierarchy across super-region, region, and country. The user can choose to require that the sum of the country random effects within a region is zero and similarly for regions within super regions. The random effects estimate systematic variation in the data across countries, regions and super-regions.
Because DisMod-MR is a variant of the generalised negative binomial model, the variance of the gamma distribution used in the negative binomial can be parameterised to be a function of the Z i study parameters if the analyst so chooses. In other words, if studies of varying quality or method are expected to be more heterogeneous, the variance of the gamma distribution can be estimated as a function of covariates.
C. Data with Different Age Intervals
Published and unpublished studies report using a set of widely discrepant age-groups. DisMod-MR has been designed to use data reported for any age interval and to yield an age pattern of prevalence. This is accomplished by generalising the observation that the prevalence for a population of age a 0 to a 2 is equal to the average prevalence of the subpopulation aged a 0 to a 1 and aged a 1 to a 2 , provided that the average is weighted by relative population size. Repeating this subdivision ad infinitum yields the weighted integral above. By integrating over the age range for any given observation, the log likelihood for each observation can be computed.
D. Expert Priors
DisMod-MR is a Bayesian meta-regression tool which allows users to specify different types of expert priors. We explain the main types of expert priors that can be used for the estimation of prevalence and how they are implemented in the estimation of the likelihood above.
For IHD, the expert priors were as follows. It was assumed there was no remission from IHD back to non-IHD. The age range was set as 0-100 (though IHD almost exclusively affects adults) with knots at 0, 10, 20 or 25, 30 or 35, 40, 50, 60, 70, 80, and 100. Prevalence was assumed to increase with age. Incidence and prevalence set to zero at age less than one year old.
Smoothness
Based on knowledge of the general biological, environmental, or social determinants of disease patterns by age, we may expect that there should not be dramatic changes in prevalence as a function of age. Users can establish a prior that prevalence should change smoothly as a function of age, which effectively puts a prior view on the posterior difference in prevalence between agegroups. This is implemented as a prior on the root mean square variation of the derivative of the log of the age pattern spline model:
Age Patterns
Based on biological, clinical, or other sources, disease experts may have a view that for example cancer incidence rises with age up until some peak age group. This may be grounded in a model of cumulative mutation due to various exposures driving the development of cancer. These prior views 6 can be implemented in DisMod-MR by informative priors on the age pattern spline model. Simply setting the prior probability to zero for age patterns which violate such a constraint achieves the goal theoretically, but for computational efficiency, it is better to implement the constraint with a strong penalty. For example, a prior that an age pattern is a non-decreasing function of age is implemented as:
where clip(x, a, b) = min(max(x,a), b), and ε is a small constant like 10 -6 .
Heterogeneity
The dispersion term in the gamma distribution of the generalised negative binomial is specified as δ i = exp(η+ ζZ i ). Based on the nature of the data available on a disease, users may have a prior view on how much variation across studies represents true variation in the rates versus how much it represents variation in the way in which prevalence is measured that is not fully captured by study level covariates. If there is a lot of non-sampling variation across studies, the user can set the level of global heterogeneity to be high. This is implemented as a weakly informative prior on η, specifying η~ Uniform[a,b], where the lower-bound of the uniform distribution sets a maximum level of overdispersion allowed for the data.
E. Borrowing Strength across Different Types of Epidemiological Data
The equations and approach described for prevalence can be used for any epidemiological parameter encompassed in DisMod-MR, such as incidence, remission, or excess mortality. But for many diseases, data are sparse and often available across studies for a mixture of incidence, prevalence, remission, and excess mortality. In addition, information on cause-specific mortality is very often available from vital registration or verbal autopsy data. In fact, the GBD work on causes of death has generated cause-specific mortality estimates for 235 causes. Estimates of the prevalence of angina pectoris should logically be informed by cross-country differences in the death rate from ischemic heart disease. Likewise, where data suggest incidence is higher than ceteris paribus, we may expect prevalence to be higher.
To borrow strength across data for different epidemiological parameters in the estimation of prevalence requires some assumptions on the relationship between different epidemiological parameters. If rates have been constant over time, there is equilibrium in that relationship that can be captured in the simple two-box model shown in Web Figure 1 . This is a simplification of the fourbox model that was the basis of the internal consistency tool developed for the GBD 1990, DisMod, and its successor, DisMod 2, used for the GBD 2000 revisions. The equilibrium assumption that rates have been constant over time is not appropriate for conditions where incidence, remission, or excess mortality is rapidly changing, such as HIV, but for many conditions is a reasonable assumption and one that is preferable to ignoring all the available data on incidence, remission, excess mortality, and cause-specific mortality and focusing exclusively on the limited prevalence data that is available.
Supplementary Methods Figure 1: The two-compartment model of process for disease in a population. Compartment S contains the population susceptible to the disease and compartment C contains the population with the condition. Individuals move from S to C with incidence rate i, and from C to S with remission rate r. The susceptible population flows out of the system with withoutcondition mortality rate m, and the with-condition population flows out of the system with with-7 condition mortality rate m+f , where f is the excess mortality rate, representing quantitatively the increase in mortality for individuals with the condition.
The meta-regression component of DisMod-MR can be estimated simultaneously using data on all the epidemiological parameters in Web Figure 1 . If the user chooses to estimate consistent parameter values, DisMod-MR estimates the likelihood function for incidence, remission, and excess mortality using observations on prevalence, incidence, excess mortality, and cause-specific mortality. These additional epidemiological rates are generally estimated using the same model as for the prevalence data described above. In the case of relative mortality risk data and standardised mortality rate data, the negative binomial likelihood is replaced by a log-normal model, and in the case of duration data, a model with a normal likelihood is used.
For IHD, the disease model differed from the general model in Supplementary Methods Figure 1 above because of the assumption of no remission, as shown below. Data availability for the epidemiologic parameters (incidence, prevalence, mortality, excess mortality) differed according to IHD sequela. For angina pectoris, almost all the studies measured prevalence. For AMI, we reviewed survey studies of prevalent prior MI and found that the results of these studies suffered from imperfect accuracy of the measurement methods (usually self-report and resting ECG changes) are likely unreliable across populations. We therefore relied exclusively on studies of AMI incidence and case fatality. Heart failure data were a mixture of incidence, prevalence, and event rate (first ever or repeat events, gathered from hospital data).
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F.
Posterior Estimation by Region DisMod-MR estimates the global meta-regression for each epidemiological parameter independently or all together, assuming consistency for the global means, if the user so chooses. In consistent estimation, consistency is always enforced for the reference levels of the covariates (i.e. without random effects, with the average of country-level effects, and with the selected reference values for cross-walk effects). In either case, however, the age fixed effects are held constant across all countries and regions and across males and females. Where there are sufficient data, however, by region, DisMod-MR can also be used to allow for regional variation in the age-sex pattern. Regional variation in the age-sex pattern of results is captured through the empirical Bayes approach to hierarchical modeling, where the global estimates are used to produce empirical priors for the estimation of region-sex posteriors. The global meta-regression results are used as a prior in Bayes theorem along with the data in the region to generate a posterior estimation for the region. This is implemented by taking the fixed effects and random effects to be constant at their mean values during posterior estimation, and using the regional predicted age pattern from the global fit to produce a mean and standard deviation for the regional age pattern. For example, the age-sex pattern for pancreatitis is markedly different for females and males. In women, pancreatitis tends to steadily rise with age where in males there are much higher rates than women at younger ages due to alcoholic pancreatitis. Assuming a fixed age-sex pattern makes the initial global meta-regression results inconsistent with the observed data in either sex. By estimating the posterior values for each regionsex group separately, where the data are strong, regional age-sex patterns that differ from the global pattern can be estimated. An important component of the posterior stage of the estimation is to determine how heterogeneous the data are in a region due to non-sampling error as opposed to variation in the true rates across countries within a region. The user can set the level of local heterogeneity due to non-sampling error by setting a weakly informative prior on η, the log of the reference-level over-dispersion parameter. For the purposes of model development, three ranges of uniform distribution were generally used, corresponding to restricting delta to overlapping ranges [1, 9] , [3, 27] , and [9, 81] .
The lowest level of the spatial hierarchy in DisMod-MR is the country level, reflected both in the country-level random effects and country-level fixed effect covariates (when applicable). After fitting a model at the regional level with all relevant data, the resulting posterior distribution is used to make country-level predictions. These predictions have the same age-sex pattern for all countries within a GBD region, but shifted levels based on fixed effect and random effects. Regional predictions that take country-level variation into account are then produced by taking the population-weighted average of the country-level predictions.
Acute Myocardial Infarction Incidence, Western Europe, 2010: Empirical prior and posterior estimates for AMI incidene in Western Europe, males, 2010. Dashed line with horizontal bars shows the mean and standard deviation of the empirical priors. Solid line with grey shaded region shows the mean and 95% UI of the posterior distribution. The empirical Bayes approach to hierarchical modeling permits estimation of differing age patterns in the face of differing data.
AMI Incidence Model Covariates:
X_sex: Gender X_nottroponinuse: 1 if the diagnostic test in the study was not troponin X_nonfatal: 1 if the study reported non-fatal MI; X_lnASDR_B03.2: IHD age standardized death rate X_firstever: 1 if the study reported first-ever MI **Adjusted data indicated that the level of data has been adjusted (to be comparable with the case definition) based on effect of covariates. The horizontal lines represent data that have been adjusted based on study-level covariates (i.e., the case definition). The vertical lines show the confidence intervals associated with each data point. The curved thick solid blue line is the final estimate with confidence intervals shown in the area shaded in grey. The curved dotted line is the empirical prior calculated by country-level covariates in addition to sex, age, and year, as well as country, region, and superregion random effects. The small plots on the right side of the figure show the effect of covariates, the country random effect, and the residuals.
G. Predictions for Different Study Years
Because the study has multiple time periods but the data available for many conditions are sparse, we have estimated posterior values for two time windows at the region-sex level. To produce estimates for 1990, we include all data with start year 1997 or earlier in the posterior estimation. To produce estimates for 2005 and 2010, we include all data with end year 1997 or later. Country-level covariates that vary with year additionally inform the difference between 2005 and 2010 posterior estimates.
H. Estimation of 95% credible intervals
One thousand draws were taken of the posterior distributions of model covariate effects (beta coefficients). Ninety-five percent Bayesian credible intervals reported in the paper are data within the 2.5 and 97.5 percentiles of these posterior distributions. These covariate values were entered into 1,000 iterations of the estimation models. Generation of credible intervals for IHD mortality estimates is described in the companion IHD mortality paper. For estimation of non-fatal IHD outcomes (acute MI, angina, ischemic heart failure), the covariates were age-standardized IHD mortality rate and studylevel data from the systematic review. In this manner, uncertainty surrounding covariate effects was propagated forward into estimates of years lived with disability (YLD) and disability-adjusted life years (DALYs).
I. Estimation of disability in co-morbid conditions
Few epidemiologic surveys obtain information on disability and presence of multiple conditions. Simulated cohorts were created using microsimulation in order to estimate the probability that particular combinations of co-morbid conditions would be present in an individual. Age and sex specific disease prevalence was used as the probability of having a condition. The probability of having any specific combination of co-morbid conditions was calculated by assuming that the probability of each component condition was independent of the other conditions. The example below shows a microsimulation of 10 The person has chest pain that occurs with moderate physical activity, such as walking uphill or more than half a kilometer (around a quarter-mile) on level ground. After a brief rest, the pain goes away. 
